Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

Repare Therapeutics, the Canada-based oncology therapy developer that counts pharmaceutical firms Celgene and Bristol Myers Squibb (BMS) as investors, closed its initial public offering at $253m yesterday.

The company raised $220m when it floated on the Nasdaq Global Select Market on Friday last week, upgrading the offering from 10 million to 11 million shares and pricing them at the top of the $18 to $20 range.

Joint book-running managers Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler subsequently took…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn